Atherosclerosis surrogate imaging trials come of age: For better or for worse?

Current Cardiology Reports

Volumn 10, Issue 6, 2008, Pages 521-525

  Davidson, Michael H ^a   Dembowski, Ewa ^b  

^a RADIANT RESEARCH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; AVASIMIBE; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ESTER TRANSFER PROTEIN; EZETIMIBE; GLIMEPIRIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PACTIMIBE; PIOGLITAZONE; PLACEBO; PRAVASTATIN; RIMONABANT; ROSUVASTATIN; SIMVASTATIN; TORCETRAPIB;

ARTERIAL WALL THICKNESS; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; ATHEROMA; ATHEROSCLEROSIS; B SCAN; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FAMILIAL HYPERCHOLESTEROLEMIA; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INTRAVASCULAR ULTRASOUND; MONOTHERAPY; NONHUMAN; STROKE;

AGE FACTORS; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CAROTID ARTERY DISEASES; CORONARY ARTERY DISEASE; DRUG DESIGN; HUMANS; TUNICA INTIMA; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 58249091563     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-008-0081-6     Document Type: Article

References (23)

1. DiMasi JA, Hansen RN, Grabowski HG: The price of innovation: new estimates of drug development costs. J Health Econ 2003, 22:151-185.
2. Smilde TJ, van Wissen S, Wollersheim H, et al.: Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomised, double-blind trial. Lancet 2001, 357:577-581.
3. Nissen SE, Tuzcu EM, Schoenhagen P, et al.: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 2004, 291:1071-1080.
4. Ridker PM, Morrow DA, Rose LM, et al.: Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol 2005, 45:1644-1648.
5. LaRosa JC, Grundy SM, Waters DD, et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1435.
6. Pedersen TR, Faergeman O, Kastelein JJ, et al.: High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction:AThe IDEAL study: a randomized controlled trial. JAMA 2005, 294:2437-2445.
7. Nissen SE, Tuzcu EM, Brewer HB, et al.: Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 2006, 354:1253-1263.
8. Meuwese MC, Duivenvoorden R, Davidson MH, et al.: Effect of ACAT inhibition on progression of carotid atherosclerosis in patients with familial hypercholesterolemia. The CAPTIVATE study. Poster presented at the Drugs Affecting Lipid Metabolism meeting. New York, NY; October 4-7, 2007.
9. Nissen SE, Tardif JC, Nicholls SJ, et al.: Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007, 356:1304-1316.
10. Kastelein JJ, van Leuven SI, Burgess L, et al.: Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007, 356:1620-1630.
11. Bots ML, Visseren FL, Evans GW, et al.: Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): A randomised, double-blind trial. Lancet 2007, 370:153-160.
12. Mazzone T, Meyer PM, Feinstein SB, et al.: Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: A randomized trial. JAMA 2006, 296:2572-2581.
13. Nissen SE, Nicholls SJ, Wolski K, et al.: Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: The PERISCOPE randomized controlled trial. JAMA 2008, 299:1561-1573.
14. Crouse JR 3rd, Raichlen JS, Riley WA, et al.: Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: The METEOR trial. JAMA 2007, 297:1344-1353.
15. Nissen SE, Nicholls SJ, Wolski K, et al.: Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: The STRADIVARIUS randomized controlled trial. JAMA 2008, 299: 1547-1560.
16. Kastelein JJ, Akdim F, Stroes ES, et al.: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008, 358: 1431-1443.
17. Barter PJ, Caulfield M, Eriksson M, et al.: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109-2122.
18. Dormandy JA, Charbonnel B, Eckland DJ, et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366: 1279-1289.
19. Nissen SE, Nicholls SJ, Sipahi I, et al.: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA 2006, 295: 1556-1565.
20. Simon T, Boutouyrie P, Gompel A, et al.: Rationale, design and methods of the CASHMERE study. Fundam Clin Pharmacol 2004, 18: 131-138.
21. Deedwania P, Barter P, Carmena R, et al.: Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: Analysis of the Treating to New Targets study. Lancet 2006, 368: 919-928.
22. Nicholls SJ, Tuzcu EM, Kalidindi S, et al.: Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: A pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol 2008, 52: 255-262.
23. ClinicalTrials.gov: Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant (Auditor). Available at http://clinicaltrials.gov/ct2/show/NCT00228176?term=AUDITOR&rank=1. Accessed August 26, 2008.